Global Control of Pneumococcal Infections by Pneumococcal Vaccines

Overview

Journal Trop Med Health

Specialty Tropical Medicine

Date 2014 Nov 27

PMID 25425955

Citations 8

Authors

Kazunori Oishi

Kazuyo Tamura

Yukihiro Akeda

Affiliations

Soon will be listed here.

Abstract

Streptococcus pneumoniae is a major worldwide cause of morbidity and mortality. Pneumococcal carriage is considered to be an important source of horizontal spread of this pathogen within the community. Pneumococcal conjugate vaccine (PCV) is capable of inducing serotype-specific antibodies in sera of infants, and has been suggested to reduce nasopharyngeal carriage of vaccine-type pneumococci in children. PCV is generally immunogenic for pediatric patients with invasive pneumococcal disease, with an exception for the infecting serotypes. Based on evidences from the clinical trials of PCV, the health impact of childhood pneumococcal pneumonia appears to be high in developing countries where most of global childhood pneumonia deaths occur. PCV vaccination may prevent hundreds of deaths per 100,000 children vaccinated in developing countries, while PCV vaccination is expected to prevent less than 10 deaths per 100,000 children vaccinated in the developed countries. Therefore, the WHO has proposed a strategy to reduce the incidence of severe pneumonia by 75% in child less than 5 years of age compared to 2010 levels by 2025.

Citing Articles

Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012-2024.

Lin T, Chiu C, Woo P, Razak Muttalif A, Dhar R, Choon Kit L Hum Vaccin Immunother. 2024; 20(1):2417554.

PMID: 39478351 PMC: 11533800. DOI: 10.1080/21645515.2024.2417554.

Genotypic and phenotypic characteristics of Streptococcus pneumoniae from community-acquired pneumonia patients and healthy asymptomatic participants in Sichuan province, China.

Peng S, Ren H, Deng J, Zhao N, Li Y, Li M BMC Infect Dis. 2021; 21(1):1030.

PMID: 34598707 PMC: 8485506. DOI: 10.1186/s12879-021-06737-w.

Molecular epidemiology of Streptococcus pneumoniae isolated from pediatric community-acquired pneumonia in pre-conjugate vaccine era in Western China.

Liang Z, Fu J, Li L, Yi R, Xu S, Chen J Ann Clin Microbiol Antimicrob. 2021; 20(1):4.

PMID: 33407509 PMC: 7788854. DOI: 10.1186/s12941-020-00410-x.

Risk factors associated with carriage in children under five years old with acute respiratory infection in Niger.

Dan Dano I, Ousmane S, Moumouni K, Lagare A, Issa I, Testa J Pan Afr Med J. 2019; 33:239.

PMID: 31692895 PMC: 6814941. DOI: 10.11604/pamj.2019.33.239.15945.

Decline in Child Hospitalization and Mortality After the Introduction of the 7-Valent Pneumococcal Conjugative Vaccine in Rwanda.

Rurangwa J, Rujeni N Am J Trop Med Hyg. 2016; 95(3):680-2.

PMID: 27430538 PMC: 5014278. DOI: 10.4269/ajtmh.15-0923.

References

Burton R, Nahm M . Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006; 13(9):1004-9. PMC: 1563573. DOI: 10.1128/CVI.00112-06. View

OBrien K, Wolfson L, Watt J, Henkle E, Deloria-Knoll M, McCall N . Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374(9693):893-902. DOI: 10.1016/S0140-6736(09)61204-6. View

Madhi S, Klugman K . A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004; 10(8):811-3. PMC: 7095883. DOI: 10.1038/nm1077. View

Scott J, Brooks W, Peiris J, Holtzman D, Mulholland E . Pneumonia research to reduce childhood mortality in the developing world. J Clin Invest. 2008; 118(4):1291-300. PMC: 2276784. DOI: 10.1172/JCI33947. View

Concepcion N, Frasch C . Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001; 8(2):266-72. PMC: 96047. DOI: 10.1128/CDLI.8.2.266-272.2001. View

Cutts F, Zaman S, Enwere G, Jaffar S, Levine O, Okoko J . Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005; 365(9465):1139-46. DOI: 10.1016/S0140-6736(05)71876-6. View

Williams B, Gouws E, Boschi-Pinto C, Bryce J, Dye C . Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002; 2(1):25-32. DOI: 10.1016/s1473-3099(01)00170-0. View

Dagan R, Givon-Lavi N, Zamir O, Fraser D . Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J. 2003; 22(6):532-40. DOI: 10.1097/01.inf.0000069761.11093.c3. View

Whitney C, Farley M, Hadler J, Harrison L, Bennett N, Lynfield R . Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003; 348(18):1737-46. DOI: 10.1056/NEJMoa022823. View

10.

Otsuka T, Chang B, Shirai T, Iwaya A, Wada A, Yamanaka N . Individual risk factors associated with nasopharyngeal colonization with Streptococcus pneumoniae and Haemophilus influenzae: a Japanese birth cohort study. Pediatr Infect Dis J. 2013; 32(7):709-14. DOI: 10.1097/INF.0b013e31828701ea. View

11.

Hill P, Akisanya A, Sankareh K, Cheung Y, Saaka M, Lahai G . Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis. 2006; 43(6):673-9. DOI: 10.1086/506941. View

12.

Qazi S, Aboubaker S, MacLean R, Fontaine O, Mantel C, Goodman T . Ending preventable child deaths from pneumonia and diarrhoea by 2025. Development of the integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea. Arch Dis Child. 2015; 100 Suppl 1:S23-8. DOI: 10.1136/archdischild-2013-305429. View

13.

Tamura K, Matsubara K, Ishiwada N, Nishi J, Ohnishi H, Suga S . Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valent pneumococcal conjugate vaccine following invasive pneumococcal disease. Vaccine. 2014; 32(13):1444-50. DOI: 10.1016/j.vaccine.2014.01.031. View

14.

. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec. 1999; 74(23):177-83. View

15.

. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine,.... Pediatrics. 2000; 106(2 Pt 1):362-6. DOI: 10.1542/peds.106.2.362. View

16.

Musher D, Chapman A, Goree A, Jonsson S, Briles D, Baughn R . Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis. 1986; 154(2):245-56. DOI: 10.1093/infdis/154.2.245. View

17.

Bogaert D, de Groot R, Hermans P . Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4(3):144-54. DOI: 10.1016/S1473-3099(04)00938-7. View

18.

Klugman K, Madhi S, Huebner R, Kohberger R, Mbelle N, Pierce N . A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003; 349(14):1341-8. DOI: 10.1056/NEJMoa035060. View

19.

Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O . Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996; 174(6):1271-8. DOI: 10.1093/infdis/174.6.1271. View